• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » UK Sets Three New Post-Brexit Policies for Clinical Trials

UK Sets Three New Post-Brexit Policies for Clinical Trials

January 11, 2021

In its ongoing effort to replace EU clinical trial policies with UK-specific guidance, the Medicines and Healthcare products Regulatory Agency (MHRA) has issued three clinical trial guidances on registering and publishing results of trials, submitting safety reports and making substantial changes to trial applications.

Trials conducted in the UK should register with and report results to one of the international trial databases, according to the first guidance, such as ClinicalTrials.gov in the U.S. or the International Standard Randomized Controlled Trial Number (ISRCTN) registry recognized by the World Health Organization. Trials with sites in both the UK and the EU can use the EU Clinical Trials Register.

The second guidance directs trials to submit Suspected Unexpected Serious Adverse Reaction (SUSAR) reports through the MHRA gateway, the eSUSAR website or MHRA’s Individual Safety Case Reports submission portal. For trials operating in both the UK and the EU, SUSAR reports must be submitted to MHRA, the relevant EU member state and the European Medicines Agency’s Eudravigilance Clinical Trial Module.

Sponsors that need to make substantial amendments to their trial applications, such as a change of sponsor or legal representative or addition of a license holder to the existing marketing authorization, must inform both MHRA and the UK’s Regulatory Ethics Committee, according to the third guidance.

Read the three guidances here: https://bit.ly/35nq8x8, https://bit.ly/39eKoSX and https://bit.ly/39eKpX1.

COVID-19
  • Related Directories

    Olumiant (baricitinib)

    Veklury (remdesivir)

    Comirnaty (COVID-19 Vaccine, mRNA)

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing